Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 2
1996 4
1997 7
1998 12
1999 15
2000 20
2001 28
2002 15
2003 12
2004 17
2005 10
2006 9
2007 14
2008 9
2009 17
2010 18
2011 16
2012 18
2013 17
2014 12
2015 13
2016 15
2017 19
2018 13
2019 12
2020 15
2021 8
2022 4
2023 4
2024 12
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

360 results

Results by year

Filters applied: . Clear all
Page 1
Targeting tumor-intrinsic S100 calcium-binding protein A1 augments antitumor immunity and potentiates immunotherapy efficacy.
Guo Y, Wan R, Duan J, Yuan L, Wang Z, Zhong J, Zhang X, Ma Z, Bai H, Wang J. Guo Y, et al. Signal Transduct Target Ther. 2025 Mar 17;10(1):99. doi: 10.1038/s41392-025-02190-2. Signal Transduct Target Ther. 2025. PMID: 40090947 Free PMC article.
Here, we uncovered the potential of plasma S100 calcium-binding protein A1 (S100A1) for determining ICB efficacy via liquid biopsy of patients with lung cancer. Multiomics and functional studies have suggested that tumor-intrinsic S100A1 expression correlated with a …
Here, we uncovered the potential of plasma S100 calcium-binding protein A1 (S100A1) for determining ICB efficacy via liquid biopsy of …
S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models.
Kehr D, Ritterhoff J, Glaser M, Jarosch L, Salazar RE, Spaich K, Varadi K, Birkenstock J, Egger M, Gao E, Koch WJ, Sauter M, Freichel M, Katus HA, Frey N, Jungmann A, Busch C, Mather PJ, Ruhparwar A, Busch M, Völkers M, Wade RC, Most P. Kehr D, et al. Circulation. 2025 Feb 25;151(8):548-565. doi: 10.1161/CIRCULATIONAHA.123.066961. Epub 2024 Nov 21. Circulation. 2025. PMID: 39569500 Free PMC article.
BACKGROUND: The EF-hand Ca(2+) sensor protein S100A1 has been identified as a molecular regulator and enhancer of cardiac performance. ...We hypothesized that a synthetic peptide consisting of residues 75 through 94 of S100A1 and an N-terminal solubilization tag (S1 …
BACKGROUND: The EF-hand Ca(2+) sensor protein S100A1 has been identified as a molecular regulator and enhancer of cardiac performance …
Structural insights into the regulation of RyR1 by S100A1.
Weninger G, Miotto MC, Tchagou C, Reiken S, Dridi H, Brandenburg S, Riedemann GC, Yuan Q, Liu Y, Chang A, Wronska A, Lehnart SE, Marks AR. Weninger G, et al. Proc Natl Acad Sci U S A. 2024 Jul 2;121(27):e2400497121. doi: 10.1073/pnas.2400497121. Epub 2024 Jun 25. Proc Natl Acad Sci U S A. 2024. PMID: 38917010 Free PMC article.
Here, we report cryoelectron microscopy structures of S100A1 bound to RyR1, the skeletal muscle isoform, in absence and presence of Ca(2+). Ca(2+)-free apo-S100A1 binds beneath the bridging solenoid (BSol) and forms contacts with the junctional solenoid and the shel …
Here, we report cryoelectron microscopy structures of S100A1 bound to RyR1, the skeletal muscle isoform, in absence and presence of C …
S100A1: a major player in cardiovascular performance.
Duarte-Costa S, Castro-Ferreira R, Neves JS, Leite-Moreira AF. Duarte-Costa S, et al. Physiol Res. 2014;63(6):669-81. doi: 10.33549/physiolres.932712. Epub 2014 Aug 26. Physiol Res. 2014. PMID: 25157660 Free article. Review.
In fact, S100A1 seems to normalize cardiac function after myocardial infarction. Also, S100A1 is essential in the acute response to adrenergic stimulation. ...Finally, we discuss S100A1 gene therapy and its progression so far....
In fact, S100A1 seems to normalize cardiac function after myocardial infarction. Also, S100A1 is essential in the acute respon …
Role of S100A1, S100A4, S100A8/A9 and S100B in myocardial infarction and heart failure.
Cheng B, Bian Y, Song X, Li W, Li M, Feng R. Cheng B, et al. Int Immunopharmacol. 2025 Apr 4;151:114348. doi: 10.1016/j.intimp.2025.114348. Epub 2025 Mar 1. Int Immunopharmacol. 2025. PMID: 40024216 Review.
S100 proteins, as inflammatory factors within the heart, demonstrate binding capabilities to various target proteins. Notably, S100A1, S100A4, S100A8/A9, and S100B have emerged as key players in myocardial infarction and heart failure pathophysiology. ...
S100 proteins, as inflammatory factors within the heart, demonstrate binding capabilities to various target proteins. Notably, S100A1 …
S100A1's single cysteine is an indispensable redox switch for the protection against diastolic calcium waves in cardiomyocytes.
Seitz A, Busch M, Kroemer J, Schneider A, Simon S, Jungmann A, Katus HA, Most P, Ritterhoff J. Seitz A, et al. Am J Physiol Heart Circ Physiol. 2024 Jul 1;327(1):H000. doi: 10.1152/ajpheart.00634.2023. Epub 2024 May 31. Am J Physiol Heart Circ Physiol. 2024. PMID: 38819384 Free PMC article.
To prevent glutathionylation of S100A1, we generated S100A1 variants that were unresponsive to ox-PTMs. Overexpression of wild-type (WT) and C85-deficient S100A1 protein variants in isolated CM demonstrated equal inotropic potency, as shown by equally …
To prevent glutathionylation of S100A1, we generated S100A1 variants that were unresponsive to ox-PTMs. Overexpression of wild …
Targeting S100A1 in heart failure.
Ritterhoff J, Most P. Ritterhoff J, et al. Gene Ther. 2012 Jun;19(6):613-21. doi: 10.1038/gt.2012.8. Epub 2012 Feb 16. Gene Ther. 2012. PMID: 22336719 Review.
S100A1 was shown to regulate sarcoplasmic reticulum, sarcomere and mitochondrial function by modulating target protein activity. ...Proof-of-concept studies in small and large animal models as wells as in human failing CM could demonstrate feasibility and efficacy of S1 …
S100A1 was shown to regulate sarcoplasmic reticulum, sarcomere and mitochondrial function by modulating target protein activity. ...P …
Down-regulation of S100A1 protein in patients with metabolic syndrome and its association with zinc-alpha2-glycoprotein.
Ebrahimi E, Kheirouri S, Alizadeh M. Ebrahimi E, et al. Scott Med J. 2017 Aug;62(3):88-95. doi: 10.1177/0036933017727433. Epub 2017 Aug 21. Scott Med J. 2017. PMID: 28825380
Serum levels of low- and high-density lipoprotein cholesterol, total cholesterol, triglyceride, fasting blood sugar, insulin, zinc-alpha2-glycoprotein and S100A1 protein were determined. Results Higher levels of anthropometric and lipid indices, metabolic factors an …
Serum levels of low- and high-density lipoprotein cholesterol, total cholesterol, triglyceride, fasting blood sugar, insulin, zinc-alpha2-gl …
Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein.
Okada M, Tokumitsu H, Kubota Y, Kobayashi R. Okada M, et al. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. doi: 10.1006/bbrc.2002.6761. Biochem Biophys Res Commun. 2002. PMID: 11944917
Mutagenesis study showed that amino acid residues 76-85 in S100A1 are necessary for its binding to Olopatadine. In contrast, residues 89-94 were identified as an Amlexanox-binding site in S100A1. Moreover, Olopatadine did not competitively inhibit S100A1-bind …
Mutagenesis study showed that amino acid residues 76-85 in S100A1 are necessary for its binding to Olopatadine. In contrast, residues …
Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction.
Most P, Seifert H, Gao E, Funakoshi H, Völkers M, Heierhorst J, Remppis A, Pleger ST, DeGeorge BR Jr, Eckhart AD, Feldman AM, Koch WJ. Most P, et al. Circulation. 2006 Sep 19;114(12):1258-68. doi: 10.1161/CIRCULATIONAHA.106.622415. Epub 2006 Sep 4. Circulation. 2006. PMID: 16952982
BACKGROUND: Diminished cardiac S100A1 protein levels are characteristic of ischemic and dilated human cardiomyopathy. ...CONCLUSIONS: Our novel proof-of-concept study provides evidence that downregulation of S100A1 protein critically contributes to con …
BACKGROUND: Diminished cardiac S100A1 protein levels are characteristic of ischemic and dilated human cardiomyopathy. ...CONCL …
360 results